Seven‐Day Versus 14‐Day Tegoprazan and Tetracycline‐Containing Quadruple Therapy for First‐Line Eradication of Helicobacter pylori Infection: A Randomized, Open‐Label, Noninferiority Trial

Documenti analoghi

• Tetracycline Three Times Daily Versus Four Times Daily in Bismuth‐Containing Quadruple Therapy as the First‐Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial
  di: Yu‐Ming Ding, et al.
  Pubblicazione: (2024)
• Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial
  di: Qingzhou Kong, et al.
  Pubblicazione: (2024)
• Efficacy and Safety of Vonoprazan‐Based Dual Therapies With Different Antibiotics Versus Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Prospective, Four‐Arm, Randomized Controlled Trial
  di: Jie Li, et al.
  Pubblicazione: (2026)
• Efficacy and Safety of Vonoprazan‐Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication: A Randomized Controlled Trial
  di: Jin‐Yan Zhang, et al.
  Pubblicazione: (2026)
• Low‐dose or high‐dose amoxicillin in vonoprazan‐based dual therapy for Helicobacter pylori eradication? A systematic review and meta‐analysis
  di: Kun‐Ping Ju, et al.
  Pubblicazione: (2024)